Corient Private Wealth LLC Has $65.55 Million Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Corient Private Wealth LLC boosted its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 0.0% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 278,566 shares of the biopharmaceutical company’s stock after buying an additional 81 shares during the quarter. Corient Private Wealth LLC owned approximately 0.22% of Alnylam Pharmaceuticals worth $65,549,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Regeneron Pharmaceuticals Inc. acquired a new position in shares of Alnylam Pharmaceuticals during the fourth quarter valued at $1,045,822,000. Raymond James Financial Inc. acquired a new position in Alnylam Pharmaceuticals during the 4th quarter valued at about $65,295,000. Jennison Associates LLC bought a new position in shares of Alnylam Pharmaceuticals in the 4th quarter valued at about $61,160,000. Proficio Capital Partners LLC grew its position in shares of Alnylam Pharmaceuticals by 25,929.6% during the 4th quarter. Proficio Capital Partners LLC now owns 193,660 shares of the biopharmaceutical company’s stock worth $45,570,000 after buying an additional 192,916 shares during the period. Finally, Strategic Financial Concepts LLC bought a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth approximately $41,529,000. 92.97% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have commented on ALNY shares. Sanford C. Bernstein lowered their target price on shares of Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating for the company in a report on Tuesday, January 7th. HC Wainwright lifted their price objective on Alnylam Pharmaceuticals from $400.00 to $500.00 and gave the stock a “buy” rating in a research note on Monday, February 24th. Piper Sandler restated an “overweight” rating and set a $296.00 target price on shares of Alnylam Pharmaceuticals in a report on Monday, November 18th. JPMorgan Chase & Co. upped their price target on Alnylam Pharmaceuticals from $272.00 to $280.00 and gave the company a “neutral” rating in a research note on Tuesday, March 11th. Finally, William Blair reissued an “outperform” rating on shares of Alnylam Pharmaceuticals in a research note on Wednesday, February 26th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $304.26.

Alnylam Pharmaceuticals Trading Up 0.0 %

Shares of Alnylam Pharmaceuticals stock opened at $241.76 on Monday. The stock has a market cap of $31.30 billion, a P/E ratio of -111.41 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a 12-month low of $141.98 and a 12-month high of $304.39. The business’s 50 day moving average is $255.17 and its 200-day moving average is $259.96. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). Equities research analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Phillip A. Sharp sold 11,250 shares of the business’s stock in a transaction that occurred on Thursday, January 23rd. The stock was sold at an average price of $275.00, for a total transaction of $3,093,750.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Kevin Joseph Fitzgerald sold 663 shares of the firm’s stock in a transaction on Friday, February 14th. The shares were sold at an average price of $255.21, for a total value of $169,204.23. Following the sale, the executive vice president now directly owns 14,321 shares of the company’s stock, valued at $3,654,862.41. This represents a 4.42 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 71,234 shares of company stock valued at $19,958,097 over the last 90 days. 1.50% of the stock is currently owned by insiders.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.